<?xml version='1.0' encoding='utf-8'?>
<document id="23990572"><sentence text="Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia."><entity charOffset="14-24" id="DDI-PubMed.23990572.s1.e0" text="efavirenz-" /><entity charOffset="29-39" id="DDI-PubMed.23990572.s1.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.23990572.s1.e0" e2="DDI-PubMed.23990572.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23990572.s1.e0" e2="DDI-PubMed.23990572.s1.e1" /></sentence><sentence text="We investigated the population pharmacokinetics and pharmacogenetics of efavirenz in 307 patients coinfected with human immunodeficiency virus and tuberculosis and included in the Cambodian Early vs Late Initiation of Antiretrovirals trial (CAMELIA) in Cambodia"><entity charOffset="72-81" id="DDI-PubMed.23990572.s2.e0" text="efavirenz" /></sentence><sentence text=" Efavirenz (600 mg/d) and stavudine plus lamivudine were administered in addition to standard antituberculosis treatment, including rifampicin and isoniazid"><entity charOffset="1-10" id="DDI-PubMed.23990572.s3.e0" text="Efavirenz" /><entity charOffset="26-35" id="DDI-PubMed.23990572.s3.e1" text="stavudine" /><entity charOffset="41-51" id="DDI-PubMed.23990572.s3.e2" text="lamivudine" /><entity charOffset="132-142" id="DDI-PubMed.23990572.s3.e3" text="rifampicin" /><entity charOffset="147-156" id="DDI-PubMed.23990572.s3.e4" text="isoniazid" /><pair ddi="false" e1="DDI-PubMed.23990572.s3.e0" e2="DDI-PubMed.23990572.s3.e0" /><pair ddi="false" e1="DDI-PubMed.23990572.s3.e0" e2="DDI-PubMed.23990572.s3.e1" /><pair ddi="false" e1="DDI-PubMed.23990572.s3.e0" e2="DDI-PubMed.23990572.s3.e2" /><pair ddi="false" e1="DDI-PubMed.23990572.s3.e0" e2="DDI-PubMed.23990572.s3.e3" /><pair ddi="false" e1="DDI-PubMed.23990572.s3.e0" e2="DDI-PubMed.23990572.s3.e4" /><pair ddi="false" e1="DDI-PubMed.23990572.s3.e1" e2="DDI-PubMed.23990572.s3.e1" /><pair ddi="false" e1="DDI-PubMed.23990572.s3.e1" e2="DDI-PubMed.23990572.s3.e2" /><pair ddi="false" e1="DDI-PubMed.23990572.s3.e1" e2="DDI-PubMed.23990572.s3.e3" /><pair ddi="false" e1="DDI-PubMed.23990572.s3.e1" e2="DDI-PubMed.23990572.s3.e4" /><pair ddi="false" e1="DDI-PubMed.23990572.s3.e2" e2="DDI-PubMed.23990572.s3.e2" /><pair ddi="false" e1="DDI-PubMed.23990572.s3.e2" e2="DDI-PubMed.23990572.s3.e3" /><pair ddi="false" e1="DDI-PubMed.23990572.s3.e2" e2="DDI-PubMed.23990572.s3.e4" /><pair ddi="false" e1="DDI-PubMed.23990572.s3.e3" e2="DDI-PubMed.23990572.s3.e3" /><pair ddi="false" e1="DDI-PubMed.23990572.s3.e3" e2="DDI-PubMed.23990572.s3.e4" /></sentence><sentence text=" Blood samples were obtained a mean of 14 hours after efavirenz intake at weeks 2 and 6 after initiation of efavirenz and weeks 22 (efavirenz plus antituberculosis drugs) and 50 (efavirenz alone) after initiation of antituberculosis treatment"><entity charOffset="54-63" id="DDI-PubMed.23990572.s4.e0" text="efavirenz" /><entity charOffset="108-117" id="DDI-PubMed.23990572.s4.e1" text="efavirenz" /><entity charOffset="132-141" id="DDI-PubMed.23990572.s4.e2" text="efavirenz" /><entity charOffset="179-188" id="DDI-PubMed.23990572.s4.e3" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.23990572.s4.e0" e2="DDI-PubMed.23990572.s4.e0" /><pair ddi="false" e1="DDI-PubMed.23990572.s4.e0" e2="DDI-PubMed.23990572.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23990572.s4.e0" e2="DDI-PubMed.23990572.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23990572.s4.e0" e2="DDI-PubMed.23990572.s4.e3" /><pair ddi="false" e1="DDI-PubMed.23990572.s4.e1" e2="DDI-PubMed.23990572.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23990572.s4.e1" e2="DDI-PubMed.23990572.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23990572.s4.e1" e2="DDI-PubMed.23990572.s4.e3" /><pair ddi="false" e1="DDI-PubMed.23990572.s4.e2" e2="DDI-PubMed.23990572.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23990572.s4.e2" e2="DDI-PubMed.23990572.s4.e3" /></sentence><sentence text=" Ten patients participated in an extensive pharmacokinetic study after week 50" /><sentence text=" CYP2B6 G516T and C485-18T polymorphisms were the most significant covariates, with weight showing a significant minor effect" /><sentence text=" Change in efavirenz apparent clearance in patients taking both efavirenz and antituberculosis treatment was highly dependent on NAT2 polymorphism, as a possible surrogate of isoniazid exposure"><entity charOffset="11-20" id="DDI-PubMed.23990572.s7.e0" text="efavirenz" /><entity charOffset="64-73" id="DDI-PubMed.23990572.s7.e1" text="efavirenz" /><entity charOffset="175-184" id="DDI-PubMed.23990572.s7.e2" text="isoniazid" /><pair ddi="false" e1="DDI-PubMed.23990572.s7.e0" e2="DDI-PubMed.23990572.s7.e0" /><pair ddi="false" e1="DDI-PubMed.23990572.s7.e0" e2="DDI-PubMed.23990572.s7.e1" /><pair ddi="false" e1="DDI-PubMed.23990572.s7.e0" e2="DDI-PubMed.23990572.s7.e2" /><pair ddi="false" e1="DDI-PubMed.23990572.s7.e1" e2="DDI-PubMed.23990572.s7.e1" /><pair ddi="false" e1="DDI-PubMed.23990572.s7.e1" e2="DDI-PubMed.23990572.s7.e2" /></sentence><sentence text=" Patients carrying the CYP2B6 516 TT genotype and slow-acetylation NAT2 phenotype had the lowest efavirenz apparent clearance"><entity charOffset="97-106" id="DDI-PubMed.23990572.s8.e0" text="efavirenz" /></sentence><sentence text=" These data suggest that the inducing effect of rifampicin is counterbalanced by a concentration-dependant inhibitory effect of isoniazid on efavirenz clearance"><entity charOffset="48-58" id="DDI-PubMed.23990572.s9.e0" text="rifampicin" /><entity charOffset="128-137" id="DDI-PubMed.23990572.s9.e1" text="isoniazid" /><entity charOffset="141-150" id="DDI-PubMed.23990572.s9.e2" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.23990572.s9.e0" e2="DDI-PubMed.23990572.s9.e0" /><pair ddi="false" e1="DDI-PubMed.23990572.s9.e0" e2="DDI-PubMed.23990572.s9.e1" /><pair ddi="false" e1="DDI-PubMed.23990572.s9.e0" e2="DDI-PubMed.23990572.s9.e2" /><pair ddi="false" e1="DDI-PubMed.23990572.s9.e1" e2="DDI-PubMed.23990572.s9.e1" /><pair ddi="false" e1="DDI-PubMed.23990572.s9.e1" e2="DDI-PubMed.23990572.s9.e2" /></sentence><sentence text=" " /></document>